title: Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
abstract: OBJECTIVE
  This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients.
  
  
  RESULTS
  Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm2 to 2.7 mm2. There was a significant increase in the greatest linear dimension (GLD) from 1280.3 microm to 2065.7 microm at the 24-week follow-up.
  
  
  CONCLUSIONS
  Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.
authors.affiliation: Hospital Universitario Clínico San Carlos, Madrid, Spain. calvo_glez@yahoo.es
authors.forename: C
authors.initials: C
authors.lastname: Calvo-González
authors.forename: J
authors.initials: J
authors.lastname: Reche-Frutos
authors.forename: J
authors.initials: J
authors.lastname: Donate-López
authors.forename: J
authors.initials: J
authors.lastname: García-Feijoó
authors.forename: M
authors.initials: M
authors.lastname: Leila
authors.forename: C
authors.initials: C
authors.lastname: Fernández-Pérez
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Sánchez
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D011446:Prospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib